The global Cell and Gene Therapy Manufacturing Market is witnessing exponential growth, with market value estimated at USD 39.76 billion in 2026 and projected to reach USD 336.25 billion by 2036, growing at a CAGR of 23.8% during the forecast period. Increasing adoption of personalized medicine, expanding clinical pipelines for gene and cell therapies, and rising investments in viral vector production and commercial-scale manufacturing are significantly contributing to market growth.
The market was valued at USD 32.12 billion in 2025 and is projected to create an incremental opportunity of USD 296.49 billion between 2026 and 2036. Biopharmaceutical companies, CDMOs, and research organizations are increasingly focusing on automated manufacturing platforms, scalable production technologies, and advanced quality control systems to improve production efficiency and regulatory compliance.
Market Growth Drivers
- Increasing demand for personalized and regenerative medicine therapies
• Rising investments in viral vector and cell therapy manufacturing infrastructure
• Growing number of clinical trials and therapy approvals globally
• Expanding adoption of commercial-scale manufacturing technologies
• Increasing reliance on contract manufacturing organizations (CDMOs)
Get detailed market forecasts, competitive benchmarking, and pricing trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16515
Emerging Trends
- Growing development of automated and closed-system manufacturing platforms
• Increasing adoption of AI-driven process optimization technologies
• Rising demand for scalable viral vector production capabilities
• Expansion of allogeneic and autologous therapy manufacturing
• Increasing integration of digital quality monitoring and analytics systems
Regional Insights
- North America: Leads the global market due to strong biotechnology infrastructure, increasing therapy approvals, and rising investments in advanced biologics manufacturing.
- Europe: Strong growth supported by expanding cell and gene therapy research activities and increasing regulatory support for advanced therapeutics.
- Asia-Pacific: Fastest-growing region driven by expanding biotechnology investments, increasing CDMO presence, and growing manufacturing capabilities across China, Japan, South Korea, and India. South Korea is projected to grow at a CAGR of 18.4% during the forecast period.
- Latin America: Emerging opportunities supported by improving healthcare infrastructure and increasing biopharmaceutical investments.
- Middle East & Africa: Growing market fueled by rising healthcare modernization initiatives and increasing investments in biotechnology infrastructure.
Competitive Landscape
The cell and gene therapy manufacturing market remains highly competitive with companies focusing on scalable production technologies, viral vector manufacturing expansion, and advanced therapy process optimization.
Key players include:
Lonza Group, Thermo Fisher Scientific, Catalent Inc., WuXi Advanced Therapies, Fujifilm Diosynth Biotechnologies, Samsung Biologics, BlueRock Therapeutics (Bayer), Miltenyi Biotec, Minaris Regenerative Medicine, Vigene Biosciences
Strategic Outlook
The cell and gene therapy manufacturing market is evolving from small-scale clinical production toward industrial-scale advanced therapy manufacturing ecosystems. Future market growth will be shaped by:
- Expansion of commercial-scale manufacturing facilities
• Increasing adoption of automated and modular manufacturing systems
• Rising investments in viral vector and cell processing technologies
• Integration of AI-driven monitoring and quality assurance platforms
• Stronger focus on process scalability, efficiency, and regulatory compliance
In 2026, gene therapy manufacturing is expected to account for 63.9% of the therapy type segment, driven by increasing demand for vector-based therapies and expanding commercialization activities. Commercial-scale manufacturing is projected to dominate with a 67.5% share owing to rising approvals of advanced therapies and increasing global production demand.
Conclusion
With increasing demand for advanced therapeutics, growing investments in scalable manufacturing technologies, and rising commercialization of cell and gene therapies, the cell and gene therapy manufacturing market is expected to witness sustained long-term growth. The market presents strong opportunities for companies investing in automated production systems, viral vector technologies, and next-generation biomanufacturing innovation.
Request Sample Report with Complete Market Breakdowns and Growth Estimates:
https://www.futuremarketinsights.com/reports/cell-and-gene-therapy-manufacturing-market
Have specific requirements or need assistance on report pricing or limited budget? Please contact us – sales@futuremarketinsights.com
About Future Market Insights (FMI)
Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.
